ClinicalTrials.gg
Active, not recruitingNCT05691361Updated Jun 16, 2026

Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients

A Phase 1/2 interventional study of ADX-324 and Placebo in Hereditary Angioedema, sponsored by ADARx Pharmaceuticals, Inc.. Active, not recruiting at 1 site in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-16.

Sponsored by ADARx Pharmaceuticals, Inc. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
53
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-15

Among 26 studies in Angioedemas, Hereditary with a site in Australia — 7 open to participants now, 12 under way, 8 of them phase 3. Angioedemas, Hereditary · Australia.

Planned enrollment
16th of 24
53 · median 90
Started
2022
with 5 others
Phase 1/2
3 of 26
none open now
Primary completion
2027-12
later than 6 of 11 live
Registered
16th of 26
by date
Lead sponsor
3 of 26
ADARx Pharmaceuticals, Inc.

Among the 26 studies in Angioedemas, Hereditary with a site in Australia, this one is the 16th largest by planned enrollment of the 24 interventional ones that give a count, is one of 6 that started in 2022, is one of 3 in phase 1/2, reaches primary completion later than 6 of the 11 other live ones, and was the 16th registered.

Angioedemas, Hereditary

171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.

Browse Angioedemas, Hereditary studies →

Open to participants now

7 of the 26 studies in Angioedemas, Hereditary with a site in Australia are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Angioedemas, Hereditary with a site in Australia, or all of them as a file.
02

Study summary

The first-in-human Phase 1 study will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-324 in healthy volunteers (HV) and in patients with Hereditary Angioedema (HAE).

Read the detailed description

The clinical study described in this protocol is a Phase 1, single-center study evaluating safety, tolerability, PK, and PD of ADX-324.

The study consists of 2 parts:

  • Randomized, double-blind, placebo-controlled, parallel group, single ascending dose (SAD) in HV with up to 6 dose cohorts. For SAD cohorts and planned dosing; and,
  • Expansion cohort in participants with Hereditary Angioedema (HAE) at selected dose from Part A and will be open label.
03

Conditions studied

  • Hereditary Angioedema
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Part A - HV

Inclusion Criteria:

  1. Male and female adults 18 to 55 years old
  2. (BMI) between 18 and 30 kg/m2
  3. use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
  4. Willing and able to provide and comply with all study visits

Exclusion Criteria:

  1. Any significant medical history
  2. Active and/or history of malignancy in the past 5 years
  3. History of liver disease, Gilbert's syndrome, or abnormal liver function test
  4. Estimated \<60 mL/min or serum creatinine > 1.5-fold .
  5. Any active infection or acute illness
  6. Major surgery or significant traumatic injury occurring within 3 months
  7. Have any other conditions that, in the opinion of the Investigator or Sponsor, would make the participant unsuitable for inclusion, or could interfere with the participant participating in or completing the study.
  8. Positive serology tests (HepB, Hep C, )
  9. Use of any prescription, vaccines, supplements/vitamins, or over-the counter medication
  10. Treatment with another product within 30 days prior to the first study drug administration
  11. Known any allergic reactions which, in the opinion of the Investigator, would interfere with the volunteer's ability to participate in the study
  12. Known to any of the study drug ingredients.
  13. Pregnancy, intent to become pregnant during the course of the study, or lactating women

Part B - HAE

Inclusion Criteria:

  1. Male and female ≥18 years old, inclusive, at the time of signing the PICF
  2. Confirmed diagnosis of HAE Types I or II
  3. Evidence of an average of (at least) one HAE attack per month
  4. Participants must have access to, and the ability to use, acute medication(s) to treat angioedema attacks.
  5. Body mass index (BMI) between 18 and 30 kg/m2
  6. Contraception use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
  7. Willing and able to provide informed consent and comply with all study visits

Exclusion Criteria:

  1. Concurrent diagnosis of any other type of chronic angioedema
  2. History of clinically significant arterial or venous thrombosis, or current history of a clinically significant prothrombotic risk.
  3. Any significant medical history
  4. Active malignancy and/or history of malignancy in the past 5 years
  5. Any active infection or acute illness, inclusive of cold/flu or COVID-19, within 30 days prior to the first study drug administration.
  6. Major surgery or significant traumatic injury occurring within 3 months prior to signature of the PICF
  7. Have any other conditions that, in the opinion of the Investigator or Sponsor, would make the participant unsuitable for inclusion, or could interfere with the participant participating in or completing the study.
  8. Positive serology tests for human immunodeficiency virus (HIV), surface antigen (HBsAg), or virus (HCV).
  9. Use of C1-INH products, androgens, antifibrinolytics or other small molecule medications for routine prophylaxis within four half-lives prior to screening
  10. Must have documented evidence of medical history of HAE attacks
  11. Use of any prescription, vaccines, supplements/vitamins, or over-the counter medication (with the exception of oral contraceptives) within 7 days prior to the first study drug administration.
  12. Treatment with another investigational product or biologic agent within 30 days prior to the study drug administration
  13. History or presence of alcohol abuse or drug use within 30 days prior to the first study drug administration and throughout the study.
  14. Blood donation of 50 to 499 mL within 30 days prior to the first study drug administration or of >499 mL within 60 days prior to the first study drug administration.
  15. Pregnancy, intent to become pregnant during the course of the study, or lactating women.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
53 participants (estimated)

Study arms

  • Experimental
    PART A - Active ADX-324 administered to HV

    For each cohort in Part A (SAD), 8 participants will be randomized in a 3:1 ratio; 6 participants to active (ADX-324): 2 participants to control (matched placebo). Randomization will be on Day 1. Initially, 2 sentinel participants (1 active and 1 placebo) will be randomized and dosed. The sentinel participants will be evaluated for safety. The investigator's assessment and the independent medical monitor will decide upon the randomization and dosing of the 6 remaining participants (5 active and 1 placebo) according to the randomization schedule.

    Drug: ADX-324

  • Placebo comparator
    PART A- Placebo administered to HV

    For each cohort in Part A (SAD), 8 participants will be randomized in a 3:1 ratio; 6 participants to active (ADX-324): 2 participants to control (matched placebo). Randomization will be on Day 1. Initially, 2 sentinel participants (1 active and 1 placebo) will be randomized and dosed. The sentinel participants will be evaluated for safety. The investigator's assessment and the independent medical monitor will decide upon the randomization and dosing of the 6 remaining participants (5 active and 1 placebo) according to the randomization schedule.

    Drug: Placebo

  • Experimental
    PART B - ADX-324 administered to HAE participants

    This will be initiated at the dose level determined by the Safety Review Committee from SAD in HVs. The treatment of HAE participants is an open-label study.

    Drug: ADX-324

Interventions

  • siRNA duplex oligonucleotide

    Also known as: siRNA

  • DrugPlacebo

    saline

    Also known as: Saline

06

What researchers measure

Primary outcomes

  1. Safety in Healthy Volunteers

    To evaluate the safety and tolerability of ADX-324 in HVs by incidence, relationship, and severity of adverse events and serious adverse events

    Time frame: 365 days

  2. Safety in Healthy Volunteers

    To evaluate the safety and tolerability of ADX-324 in HVs by change in baseline electrocardiogram (ECG) parameters (PR, QRS, QT, and QTcF intervals)

    Time frame: 365 days

  3. Safety in Hereditary Angioedema

    To evaluate the safety and tolerability of ADX-324 in HAE by incidence, relationship, and severity of adverse events and serious adverse events

    Time frame: 365 days

Secondary outcomes

  1. Pharmacokinetics in Healthy Volunteers

    To characterize the Pharmacokinetics of ADX-324 in HVs by measuring the Maximum observed concentration (Cmax)

    Time frame: 8 days

  2. Pharmacokinetics in Healthy Volunteers

    To characterize the Pharmacokinetics of ADX-324 in HVs by measuring the Time to Cmax (Tmax)

    Time frame: 8 days

  3. Pharmacokinetics in Healthy Volunteers

    To characterize the Pharmacokinetics of ADX-324 in HVs by measuring the Area under the concentration-time curve from 0 to time of last quantifiable concentration (AUC0-last)

    Time frame: 8 days

  4. Pharmacokinetics in Healthy Volunteers

    To characterize the Pharmacokinetics of ADX-324 in HVs by measuring the Area under the concentration-time curve from 0 to infinity (AUC0-∞)

    Time frame: 8 days

  5. Pharmacokinetics in Healthy Volunteers

    To characterize the Pharmacokinetics of ADX-324 in HVs by measuring the Apparent terminal half-life (t½)

    Time frame: 8 days

  6. Pharmacokinetics in Healthy Volunteers

    To characterize the Pharmacokinetics of ADX-324 in HVs by measuring the Terminal elimination rate constant (λz)

    Time frame: 8 days

  7. Pharmacokinetics in Healthy Volunteers

    To characterize the Pharmacokinetics of ADX-324 in HVs by measuring the Total apparent body clearance (CL/F)

    Time frame: 8 days

  8. Pharmacokinetics in Healthy Volunteers

    To characterize the Pharmacokinetics of ADX-324 in HVs by measuring the Apparent volume of distribution (Vz/F)

    Time frame: 8 days

  9. Pharmacodynamics in Healthy Volunteers

    To characterize the PD of ADX-324 in HVs by the Change from base in plasma concentrations over time of pre Kallikrein (PKK)

    Time frame: 365 days

  10. Pharmacodynamics in Healthy Volunteers

    To characterize the PD of ADX-324 in HVs by the Change from base in plasma concentrations over time of Kallikrein (KK)

    Time frame: 365 days

  11. Pharmacokinetics in Hereditary Angioedema

    To characterize the PD of ADX-324 in HAE by Maximum observed concentration (Cmax) of ADX-324

    Time frame: 365 days

  12. Pharmacokinetics in Hereditary Angioedema

    To characterize the PD of ADX-324 in HAE by Time to Cmax (Tmax) of ADX-324

    Time frame: 8 days

  13. Pharmacokinetics in Hereditary Angioedema

    To characterize the PD of ADX-324 in HAE by Area under the concentration-time curve from 0 to time of last quantifiable concentration (AUC0-last) of ADX-324

    Time frame: 8 days

  14. Pharmacokinetics in Hereditary Angioedema

    To characterize the PD of ADX-324 in HAE by Area under the concentration-time curve from 0 to infinity (AUC0-∞) of ADX-324

    Time frame: 8 days

  15. Pharmacokinetics in Hereditary Angioedema

    To characterize the PD of ADX-324 in HAE by Apparent terminal half-life (t½)

    Time frame: 8 days

  16. Pharmacokinetics in Hereditary Angioedema

    To characterize the PD of ADX-324 in HAE by Terminal elimination rate constant (λz)

    Time frame: 8 days

  17. Pharmacokinetics in Hereditary Angioedema

    To characterize the PD of ADX-324 in HAE by Total apparent body clearance (CL/F)

    Time frame: 8 days

  18. Pharmacokinetics in Hereditary Angioedema

    To characterize the PD of ADX-324 in HAE by Apparent volume of distribution (Vz/F)

    Time frame: 8 days

  19. Pharmacodynamics in Hereditary Angioedema

    To characterize the PD of ADX-324 in HV by Change from base in plasma concentrations over time pre-kallikrein (PKK)

    Time frame: 365 days

  20. Pharmacodynamics in Hereditary Angioedema

    To characterize the PD of ADX-324 in HAE by Change from base in plasma concentrations over time kallikren (KK)

    Time frame: 365 days

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2022 (actual). Primary completion is estimated for Dec 2027, 60 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2022
First posted
Jan 20, 2023
StartActual
Dec 14, 2022
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Jun 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05691361
Lead sponsor
ADARx Pharmaceuticals, Inc.
Collaborators
Avance Clinical Pty Ltd.
Responsible party
Sponsor
First posted
Jan 20, 2023
Start date
Dec 14, 2022
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jun 16, 2026

Study contacts

Lauge Farnaes, MD
study director · ADARx Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Onvuzosiran sodium

Start the discussion